ArticleThe Indian journal of medical research2026
Sentinel serosurvey for Mpox virus infection among key populations in India: Evidence of sporadic past exposure beyond travel-related cases.
Article in The Indian journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives Mpox, declared a public health emergency of international concern by WHO, has demonstrated sporadic transmission globally. While India reported 66 confirmed cases predominantly linked to international travel, the possibility of silent community circulation remains unconfirmed, particularly within high-risk populations. Serological surveys are crucial for detecting past exposure, including asymptomatic infections that may be missed by clinical surveillance. This study aimed to assess the prevalence of anti-MPXV IgG and IgM antibodies and identify socio-demographic and behavioural determinants of seropositivity among key populations in India. Methods A multicentric, cross-sectional sentinel serosurvey was conducted between September 2023 to March 2024 across seven community-based organisation sites in India. A total of 1,790 participants aged 18-40 y (born after cessation of smallpox vaccination in India) were enrolled. Serological testing was performed using enzyme-linked immunosorbent assay (ELISA) for anti-MPXV IgG and IgM antibodies. Plaque reduction neutralisation test (PRNT50) was used to assess functional neutralising antibodies against both MPXV and Vaccinia virus. Results Among 1,790 participants, 14 (0.78%) tested positive for anti-MPXV IgG, with no IgM positivity detected. IgG-positive individuals were predominantly male (57.1%), aged 31-40 y (85.7%), and sexually active (75.9%). Geographic distribution ranged from 0.34% (Delhi NCR) to 2.07% (Kerala). PRNT50 assay revealed functional neutralising antibodies against MPXV in 64.3% (9/14) of IgG-positive samples, with evidence of cross-reactive immunity to Vaccinia virus in 93.9% (13/14). Interpretation and conclusions This multicentric sentinel serosurvey identified very low Mpox virus seroprevalence (0.78%) among key populations in India, suggesting limited prior exposure. The absence of IgM antibodies indicates that infections were not recent and provides no evidence of ongoing community transmission during the study period. Detection of neutralising antibodies in a subset of IgG-positive individuals supports prior Orthopoxvirus exposure. These findings establish baseline sero-epidemiological evidence for Mpox in India and underscore the importance of periodic sentinel sero surveillance for early detection and outbreak preparedness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.